Kedar V Inamdar
Overview
Explore the profile of Kedar V Inamdar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kady N, Abdelrahman S, Rauf A, Rauf A, Burgess A, Weiss J, et al.
Blood
. 2024 Dec;
145(6):597-611.
PMID: 39652777
The transcription factor GATA-binding protein 3 (GATA-3) and the transcriptional program it regulates have emerged as oncogenic drivers across diverse T-cell lymphomas (TCLs), many of which are resistant to conventional...
2.
Murga-Zamalloa C, Stone M, Gutierrez M, Hippalgaonkar N, Tariq H, Sadeh M, et al.
Am J Clin Pathol
. 2024 Feb;
161(6):586-597.
PMID: 38345307
Objectives: Because of its low frequency in adult populations and clinical and laboratory overlap with hemophagocytic lymphohistiocytosis and other T-cell lymphomas, T-cell/natural killer (NK) cell systemic, chronic, active Epstein-Barr virus...
3.
Vijayanarayanan A, Shaw B, Gibbons K, Inamdar K, Kuriakose P, Menon M
Blood Adv
. 2022 Aug;
6(24):6210-6212.
PMID: 35973157
No abstract available.
4.
Columbus-Morales I, Maahs L, Husain S, Gordon S, Inamdar K, Gonzalez H
Case Reports Hepatol
. 2020 Sep;
2020:6901514.
PMID: 32884850
Hemophagocytic lymphohistiocytosis (HLH) is a rare condition characterized by a pathologic immune dysregulation resulting in extreme inflammation. Clinical manifestations are varied but can include severe multiorgan failure and death. HLH...
5.
Murga-Zamalloa C, Inamdar K, Wilcox R
Blood Adv
. 2019 Jun;
3(11):1778-1787.
PMID: 31186254
High-risk lymphomas (HRLs) are associated with dismal outcomes and remain a therapeutic challenge. Recurrent genetic and molecular alterations, including c-myc expression and aurora A kinase (AAK) and polo-like kinase-1 (PLK1)...
6.
Merzianu M, Groman A, Hutson A, Cotta C, Brynes R, Orazi A, et al.
Am J Clin Pathol
. 2018 Jul;
150(5):393-405.
PMID: 30052721
Objectives: To assess bone marrow (BM) sampling in academic medical centers. Methods: Data from 6,374 BM samples obtained in 32 centers in 2001 and 2011, including core length (CL), were...
7.
Murga-Zamalloa C, Polk A, Hanel W, Chowdhury P, Brown N, Hristov A, et al.
Oncotarget
. 2018 Feb;
8(70):114474-114480.
PMID: 29383095
Survival following anthracycline-based chemotherapy remains poor among patients with most T-cell lymphoproliferative disorders. This may be attributed, at least in part, to cell-autonomous mechanisms of chemotherapy resistance observed in these...
8.
9.
Kezlarian B, Alhyari M, Venkataraman G, Karner K, Inamdar K, Menon M
Appl Immunohistochem Mol Morphol
. 2017 Sep;
27(3):180-184.
PMID: 28877074
Background: Classic Hodgkin lymphoma (CHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) are clinically distinct entities, with different prognostic and treatment implications. In addition, several large B-cell lymphomas and some...
10.
Gomez-Gelvez J, Salama M, Perkins S, Leavitt M, Inamdar K
Am J Clin Pathol
. 2016 Apr;
145(4):514-23.
PMID: 27124945
Objectives: We evaluated the prognostic impact of cell-of-origin classification as well as intratumoral regulatory T cells (Tregs), macrophages, and microvessel density (MVD) on 115 patients (74 in the training set...